Skip to main content

Eclipse Ventures, LLC

SEC CIK
0001908066
Latest filing
Aug 7, 2026

The latest 13F from Eclipse Ventures, LLC covers Q2 2026 (filed Aug 7, 2026): 2 long positions worth $2.57B. The top 10 holdings make up 100.0% of the portfolio, and the largest is Cerebras Systems Inc. (CBRS) at 98.3%. Livermore has 17 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
1
Est. +$2.53B
Added
0
Reduced
0
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. CBRSCerebras Systems Inc.
    98.3%$2.53BHistory
  2. OWLTOwlet, Inc.
    1.7%$44.2MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. CBRSCerebras Systems Inc.
    +$2.53BNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. CBRSCerebras Systems Inc.
    +98.28 pp0.0% → 98.3%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

None this quarter.

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

None this quarter.

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.57B
+$2.53B (+6,402.5%) vs. prior quarter
Positions
2
+1 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q2 2026, one quarter
Average holding period
1.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

16 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $399.9B (Q1 2022)

Q4 2021: $598.8MQ1 2022: $399.9BQ2 2022: $216.7MQ3 2022: $267.9MQ4 2022: $111.0MQ1 2023: $123.7MQ2 2023: $9.69MQ3 2023: $9.12MQ4 2023: $10.7MQ1 2024: $8.77MQ2 2024: $8.38MQ3 2024: $17.1MQ4 2024: $16.9MQ4 2025: $124.7MQ1 2026: $39.6MQ2 2026: $2.57B
Q4 2021Q2 2026
13F filings of Eclipse Ventures, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 7, 20262$2.57BCBRSOWLTvs. Q1 2026SEC
Q1 2026May 6, 20261$39.6MOWLTvs. Q4 2025SEC
Q4 2025Feb 12, 20261$124.7MOWLT–SEC
Q4 2024Feb 18, 20251$16.9MOWLTvs. Q3 2024SEC
Q3 2024Nov 8, 20241$17.1MOWLTvs. Q2 2024SEC
Q2 2024Aug 7, 20241$8.38MOWLTvs. Q1 2024SEC
Q1 2024May 6, 20241$8.77MOWLTvs. Q4 2023SEC
Q4 2023Feb 6, 20241$10.7MOWLTvs. Q3 2023SEC
Q3 2023Nov 2, 20231$9.12MOWLTvs. Q2 2023SEC
Q2 2023Aug 10, 20231$9.69MOWLTvs. Q1 2023SEC
Q1 2023May 2, 20233$123.7MENVXOWLTLucira Health Incvs. Q4 2022SEC
Q4 2022Feb 7, 20233$111.0MENVXOWLTLucira Health Incvs. Q3 2022SEC
Q3 2022Nov 14, 20223$267.9MENVXOWLTLucira Health Incvs. Q2 2022SEC
Q2 2022Aug 11, 20223$216.7MENVXOWLTLucira Health Incvs. Q1 2022SEC
Q1 2022Apr 27, 20223$399.9BENVXOWLTLucira Health Incvs. Q4 2021SEC
Q4 2021Apr 19, 2022Amended3$598.8MENVXOWLTLucira Health Inc–SEC